Pfizer, BioNTech Covid-19 Vaccine Authorized For Ages 6 Months Through 11 Years Old
Portfolio Pulse from Benzinga Newsdesk
The FDA has authorized the Pfizer-BioNTech COVID-19 vaccine for use in children aged 6 months to 11 years old. This is the first COVID-19 vaccine authorized for this age group in the US.
September 11, 2023 | 5:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech, as a partner in the development of the COVID-19 vaccine, could see a potential increase in revenue following the FDA's authorization for use in children aged 6 months to 11 years.
BioNTech, as a partner in the development of the COVID-19 vaccine, stands to benefit from the expanded authorization. The new age group could lead to increased sales and revenue for BioNTech in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer's COVID-19 vaccine authorization for children aged 6 months to 11 years could potentially increase the company's vaccine sales.
The FDA's authorization of Pfizer's COVID-19 vaccine for children aged 6 months to 11 years expands the potential market for the vaccine. This could lead to increased sales and revenue for Pfizer in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100